For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus
Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with stage 3 melanoma
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high